MEDICLIN (MED) AI Stock Analysis

• Market Cap: €173.85M
• Dividend Yield: 1.17%
• Average Volume (3M): 5.25K
• Price to Earnings (P/E): 5.1
• Beta (1Y): 0.18
• Revenue Growth: 4.27%
• EPS Growth: N/A
• Country: DE
• Employees: 7,292
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: 47,500,000
• 10 Day Avg. Volume: 4,347
• 30 Day Avg. Volume: 5,253
• PEG Ratio: -0.01
• Price to Book (P/B): 0.52
• Price to Sales (P/S): 0.15
• P/FCF Ratio: 3.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 77 Outperform
• Price Target: €4.00 ▲(14.29% Upside)

MEDICLIN's strong technical indicators and attractive valuation are the primary drivers of its high score. While financial performance is solid, high leverage remains a concern. The absence of earnings call data and corporate events does not impact the score.

MEDICLIN Business Overview & Revenue Model

Company Description

MEDICLIN (MED) is a leading healthcare provider focused on delivering high-quality medical services through a network of hospitals, clinics, and outpatient facilities. The company operates primarily in the healthcare sector, offering a wide range of services including inpatient and outpatient care, rehabilitation, and specialized medical treatments. MEDICLIN is committed to enhancing patient care through advanced medical technology, skilled healthcare professionals, and a patient-centered approach.

How the Company Makes Money

MEDICLIN generates revenue through multiple streams, including patient care services, which encompass hospital stays, outpatient treatments, and rehabilitation programs. The company typically bills patients and their insurance providers for these services, creating a significant revenue source. Additionally, MEDICLIN may engage in partnerships with insurance companies to provide specific healthcare plans, further diversifying its income. Other revenue streams may include specialized services and programs that cater to specific medical needs, as well as potential government funding for public health initiatives. Partnerships with pharmaceutical or medical device companies for clinical trials and research can also contribute to its earnings.

MEDICLIN Financial Statement Overview

Summary

MEDICLIN shows solid revenue and profit growth with strong gross margins. However, high leverage poses financial risks despite improving profitability metrics. Strong cash flow generation is noted, though conversion of earnings to free cash flow could be better.

Income Statement

MEDICLIN has shown consistent revenue growth with a TTM revenue growth rate of 2.20%. The gross profit margin is strong at 83.59%, indicating efficient cost management. Net profit margin improved to 3.49% TTM, reflecting enhanced profitability. However, the EBIT and EBITDA margins, while stable, suggest room for operational efficiency improvements.

Balance Sheet

The company maintains a high debt-to-equity ratio of 2.09 TTM, indicating significant leverage, which could pose financial risks. Return on equity improved to 12.59% TTM, showing better utilization of equity. The equity ratio is moderate, suggesting a balanced asset structure but with potential vulnerability due to high debt levels.

Cash Flow

MEDICLIN's free cash flow growth rate is robust at 26.84% TTM, demonstrating strong cash generation capabilities. The operating cash flow to net income ratio is 0.47, indicating adequate cash flow relative to earnings. However, the free cash flow to net income ratio of 0.44 suggests that not all earnings are translating into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	764.62M	748.80M	730.10M	704.70M	673.10M	659.90M
Gross Profit	641.99M	623.00M	594.60M	571.90M	551.00M	547.20M
EBITDA	117.77M	106.41M	101.27M	91.80M	85.43M	76.84M
Net Income	33.96M	24.84M	-10.78M	9.44M	1.46M	-9.00M
Balance Sheet
Total Assets	902.37M	905.91M	880.50M	916.11M	881.24M	887.46M
Cash, Cash Equivalents and Short-Term Investments	110.19M	107.56M	115.29M	88.04M	133.48M	100.44M
Total Debt	455.32M	464.13M	479.82M	502.67M	439.96M	486.97M
Total Liabilities	670.10M	683.17M	684.47M	706.79M	698.22M	710.62M
Stockholders Equity	231.86M	222.51M	195.92M	209.21M	183.28M	177.16M
Cash Flow
Free Cash Flow	43.38M	35.88M	40.43M	8.62M	64.96M	92.91M
Operating Cash Flow	93.20M	80.57M	78.00M	34.64M	81.97M	118.69M
Investing Cash Flow	-31.34M	-15.13M	-9.51M	-6.24M	-7.09M	-8.60M
Financing Cash Flow	-75.26M	-73.16M	-45.48M	-56.17M	-55.26M	-46.50M

MEDICLIN Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MED, the sentiment is Neutral. The current price of 3.5 is below the 20-day moving average (MA) of 3.56, above the 50-day MA of 3.27, and above the 200-day MA of 3.02, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 52.11 is Neutral, neither overbought nor oversold. The STOCH value of 25.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:MED.

MEDICLIN Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MED	77 Outperform	€173.85M	5.12	15.78%	1.17%	4.27%	―
M12	72 Outperform	€276.44M	15.48	15.61%	3.41%	6.52%	7.17%
RHK	70 Outperform	€803.26M	21.08	2.94%	0.82%	9.10%	-15.07%
LIK	66 Neutral	€103.80M	22.07	23.66%	―	0.21%	7.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MAK	41 Neutral	€22.02M	-1.64	―	―	6.87%	-94.85%